📇 Rhumatologue · MONTROUGE · (92) · Libéral

MME Maria DE OLIVEIRA

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
22 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
136 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 MONTROUGE (92)LibéralRPPS 10001019297

📊 Reconnaissance scientifique : 19/100📝 33 articles publiés🇫🇷 Publications académiques françaises (8)

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Influence scientifique

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure: The RENOVATE Randomized Clinical Trial

JAMA · 2025

📚 56 citations🎯 RCR 24.39🩺 Clinique🔓 Open Access

Lire l'abstract Crossref ↓

ImportanceHigh-flow nasal oxygen (HFNO) and noninvasive ventilation (NIV) are commonly used respiratory support therapies for patients with acute respiratory failure (ARF).ObjectiveTo assess whether HFNO is noninferior to NIV on the rates of endotracheal intubation or death at 7 days in 5 patient groups with ARF.Design, Setting, and ParticipantsThis noninferiority, randomized clinical trial enrolled hospitalized adults (aged ≥18 years; classified as 5 patient groups with ARF: nonimmunocompromised with hypoxemia, immunocompromised with hypoxemia, chronic obstructive pulmonary disease [COPD] exacerbation with respiratory acidosis, acute cardiogenic pulmonary edema [ACPE], or hypoxemic COVID-19, which was added as a separate group on June 26, 2023) at 33 hospitals in Brazil between November 2019 and November 2023 (final follow-up: April 26, 2024).InterventionsHigh-flow nasal oxygen (n = 883) or NIV (n = 883).Main Outcomes and MeasuresThe primary outcome was endotracheal intubation or death within 7 days assessed using a bayesian hierarchical model with dynamic borrowing across patient groups. Noninferiority was defined by a posterior probability of 0.992 or greater for an odds ratio (OR) less than 1.55.ResultsAmong 1800 patients, 1766 completed the study (mean age, 64 [SD, 17] years; 707 [40%] were women). The primary outcome of endotracheal intubation or death at 7 days occurred in 39% (344/883) in the HFNO group vs 38% (336/883) in the NIV group. In the immunocompromised with hypoxemia patient group, the primary outcome occurred in 57.1% (16/28) in the HFNO group vs 36.4% (8/22) in the NIV group; enrollment was stopped for futility (final OR, 1.07; 95% credible interval [CrI], 0.81-1.39; noninferiority posterior probability [NPP], 0.989). In the nonimmunocompromised with hypoxemia group, the primary outcome occurred in 32.5% (81/249) in the HFNO group vs 33.1% (78/236) in the NIV group (OR, 1.02 [95% CrI, 0.81-1.26]; NPP, 0.999). In the ACPE group, the primary outcome occurred in 10.3% (14/136) in the HFNO group vs 21.3% (29/136) in the NIV group (OR, 0.97 [95% CrI, 0.73-1.23]; NPP, 0.997). In the hypoxemic COVID-19 group, the primary outcome occurred in 51.3% (223/435) in the HFNO group vs 47.0% (210/447) in the NIV group (OR, 1.13 [95% CrI, 0.94-1.38]; NPP, 0.997). In the COPD exacerbation with respiratory acidosis group, the primary outcome occurred in 28.6% (10/35) in the HFNO group vs 26.2% (11/42) in the NIV group (OR, 1.05 [95% CrI, 0.79-1.36]; NPP, 0.992). However, a post hoc analysis without dynamic borrowing across the 5 ARF patient groups revealed some qualitatively different results in patients with COPD, immunocompromised patients, and patients with ACPE. The incidence of serious adverse events was similar (9.4% of patients in HFNO group vs 9.9% in NIV group).Conclusions and RelevanceCompared with NIV, HFNO met prespecified criteria for noninferiority for the primary outcome of endotracheal intubation or death within 7 days in 4 of the 5 patient groups with ARF. However, the small sample sizes in some patient groups and the sensitivity of the findings to the choice of analysis model suggests the need for further study in patients with COPD, immunocompromised patients, and patients with ACPE.Trial RegistrationClinicalTrials.gov Identifier: NCT03643939

Burden of Chikungunya Fever and Its Economic and Social Impacts Worldwide: A Systematic Review

Tropical medicine & international health : TM & IH · 2025

📚 6 citations🎯 RCR 2.76🔓 Open Access

Lire l'abstract Crossref ↓

ABSTRACTObjectivesThis study aimed to investigate the social and economic impacts and disease burden of Chikungunya Fever globally through a systematic literature review.MethodsWe performed a comprehensive literature search through MEDLINE (via PubMed), LILACS, and Embase databases, and grey literature, including studies of populations diagnosed with Chikungunya Fever or at risk of infection published in English, Spanish, French, or Portuguese, without date restrictions. Two reviewers independently performed study selection, data extraction, and quality assessment. Methodological quality was assessed using different tools.ResultsForty‐three publications were included. Until 2013, publications originated solely from the Asian and African continents. From 2015 onwards, South America emerged as the predominant source. Publications were classified as cost studies (25), including cost‐of‐illness (18) and program cost (6); burden of disease studies (10); cost‐outcome studies (4), including cost‐effectiveness (3) and cost‐utility (1); and quality‐of‐life studies (15). Reported total direct costs associated with Chikungunya Fever ranged from US$ 3.5 million (US Virgin Islands, 2014–2015) to US$ 83.6 billion (Region of the Americas, 2013–2015). Direct medical costs varied from US$ 308.94 (Tamil Nadu, India, 2006) to US$ 33.7 million (Réunion Island, 2005–2006). Vector control program costs ranged from US$ 888,000 annually (Greece, 2013–2017) to US$ 466 million (Brazil, 2016). Estimated disability‐adjusted life years per 100,000 population ranged from 4.53 (India, 2006) to 2432 (Region of the Americas, 2013–2015). Quality‐of‐life studies demonstrated substantial declines across multiple domains, indicating significant functional impairment due to Chikungunya Fever.ConclusionChikungunya Fever imposes a considerable economic and social burden, surpassing that of other endemic arboviral diseases such as dengue and yellow fever. These findings underscore the need for further research to accurately quantify the full scope of Chikungunya Fever‐related costs and impacts on affected populations.

Impacts of Yacon Syrup (Smallanthus sonchifolius) on Human Health: A Systematic Review of Scientific Evidence from the Last Decade

Nutrients · 2025

📚 4 citations🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Background/Objectives: Yacon syrup (Smallanthus sonchifolius) has gained attention due to its high concentration of fructooligosaccharides (FOSs) and associated health benefits. This systematic review aimed to evaluate the effects of yacon syrup on metabolic parameters and intestinal health in humans over the last decade. Methods: Following PRISMA guidelines, we conducted a systematic search in databases, including Medline (PubMed), Science Direct, Embase, Scopus, and SciELO, up to October 2024. Inclusion criteria focused on clinical trials examining the impact of yacon syrup on glycemic control, lipid profile, insulin sensitivity, appetite regulation, and gut microbiota in healthy, overweight, or obese individuals. Seven studies met the inclusion criteria, encompassing 161 participants from diverse populations. Results: Yacon syrup supplementation demonstrated significant reductions in fasting insulin, HOMA-IR, and LDL cholesterol, alongside improvements in satiety and intestinal transit time. Acute supplementation with yacon syrup had inconsistent results for postprandial glycemia and insulin levels, probably due to prior individual gut microbiota composition. Longer interventions with yacon syrup were associated with enhanced microbiota modulation and appetite regulation, particularly in women. Mild gastrointestinal discomfort was reported, but with the continued use of yacon syrup, the symptoms decreased. Yacon syrup presents promising health benefits, including improved insulin sensitivity, weight management, and gut health. However, further research is needed to establish optimal dosing and long-term safety. Conclusions: This review highlights the potential of yacon syrup as a functional supplement for metabolic and gastrointestinal health.

Cookies & analyse de trafic

MME Maria DE OLIVEIRA

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (22) — classées par pathologie

Transversal7

Revue générale4

Essai clinique2

Gériatrie2

Pharmacovigilance2

Revue / méta-analyse2

Activité physique / Rééducation1

Case report / série1

Économie santé1

Épidémiologie & registres1

IA en rhumatologie1

Microbiote1

Sjögren1

Vraie vie / RWE1

Partager cette fiche